NYSE:IQV - Iqvia Stock Price, Forecast & News

Iqvia's stock was trading at $125.42 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, IQV stock has decreased by 14.6% and is now trading at $107.14. View which stocks have been mosted impacted by Coronavirus.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 17 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Iqvia.

Iqvia is scheduled to release its next quarterly earnings announcement on Wednesday, May 6th 2020. View our earnings forecast for Iqvia.

Iqvia Holdings Inc (NYSE:IQV) announced its quarterly earnings data on Wednesday, February, 12th. The medical research company reported $1.74 EPS for the quarter, topping analysts' consensus estimates of $1.72 by $0.02. The medical research company had revenue of $2.90 billion for the quarter, compared to analysts' expectations of $2.85 billion. Iqvia had a net margin of 1.72% and a return on equity of 17.65%. Iqvia's revenue for the quarter was up 7.7% compared to the same quarter last year. During the same period in the previous year, the business earned $1.50 EPS. View Iqvia's earnings history.

Iqvia issued an update on its FY20 earnings guidance on Wednesday, February, 12th. The company provided earnings per share guidance of $7.15-7.35 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.22. The company issued revenue guidance of 11.775-12.000 billion, compared to the consensus revenue estimate of $11.84 billion.

17 Wall Street analysts have issued 12 month target prices for Iqvia's stock. Their forecasts range from $110.00 to $200.00. On average, they anticipate Iqvia's share price to reach $168.25 in the next twelve months. This suggests a possible upside of 57.0% from the stock's current price. View analysts' price targets for Iqvia.

News stories about IQV stock have trended very positive recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Iqvia earned a daily sentiment score of 4.0 on InfoTrie's scale. They also assigned news stories about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutIqvia.

Iqvia saw a decrease in short interest in the month of March. As of March 13th, there was short interest totaling 2,777,500 shares, a decrease of 22.2% from the February 27th total of 3,570,000 shares. Based on an average daily volume of 1,500,000 shares, the days-to-cover ratio is presently 1.9 days. Approximately 1.5% of the shares of the stock are short sold. View Iqvia's Current Options Chain.

Some companies that are related to Iqvia include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), PPD (PPD), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), PRA Health Sciences (PRAH), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Intrexon (XON), Precigen (PGEN), Auxly Cannabis Group (CBWTF) and Anavex Life Sciences (AVXL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Iqvia investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Paypal (PYPL), Allergan (AGN) and salesforce.com (CRM).

Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

Iqvia's stock is owned by a number of institutional and retail investors. Top institutional investors include State Street Corp (4.02%), Jackson Square Partners LLC (2.68%), FMR LLC (2.16%), Janus Henderson Group PLC (2.13%), Alliancebernstein L.P. (2.02%) and Capital Research Global Investors (1.78%). Company insiders that own Iqvia stock include Ari Bousbib, Canada Pension Plan Investment, Cpp Investment Board Private H, Group Holdings (Sbs) Advis Tpg, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Robert Parks, Ronald A Rittenmeyer and W Richard Staub. View institutional ownership trends for Iqvia.

IQV stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Farallon Capital Management LLC, Renaissance Technologies LLC, Citigroup Inc., DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main, AMF Pensionsforsakring AB, First Trust Advisors LP, and Jackson Square Partners LLC. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Group Holdings (Sbs) Advis Tpg, John Connaughton, Kevin C Knightly, Michael J Evanisko, and Michael R Mcdonnell. View insider buying and selling activity for Iqvia.

IQV stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, AustralianSuper Pty Ltd, Goldman Sachs Group Inc., Point72 Asset Management L.P., Loomis Sayles & Co. L P, Bessemer Group Inc., Assenagon Asset Management S.A., and Alliancebernstein L.P.. View insider buying and selling activity for Iqvia.

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IQV stock can currently be purchased for approximately $107.14.

Iqvia has a market capitalization of $20.61 billion and generates $11.09 billion in revenue each year. The medical research company earns $191 million in net income (profit) each year or $5.94 on an earnings per share basis. Iqvia employs 67,000 workers across the globe. View additional information about Iqvia.

The official website for Iqvia is http://www.iqvia.com/.

Iqvia's mailing address is 4820 EMPEROR BLVD, DURHAM NC, 27703. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]